<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03741088</url>
  </required_header>
  <id_info>
    <org_study_id>03.CP.0.3</org_study_id>
    <nct_id>NCT03741088</nct_id>
  </id_info>
  <brief_title>Study to Evaluate VORTX Rx (Theresa)</brief_title>
  <acronym>Theresa</acronym>
  <official_title>Multi-center, Open-labeled, Non-randomized Study to Evaluate the Acute Technical Performance and Safety Profile of the VORTX Rx® for Ablation of Primary and Metastatic Liver Tumors (Theresa Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HistoSonics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HistoSonics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multi-center, Open-labeled, Non-randomized Study to Evaluate the Acute Technical Performance&#xD;
      and Safety Profile of the VORTX Rx® for Ablation of Primary and Metastatic Liver Tumors&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will assess the technical performance of the VORTX Rx device to deliver acoustic&#xD;
      energy for cavitation-based cellular destruction. The planned duration of a single target&#xD;
      tumor will be 60 minutes or less in a single session and adjusted intra-procedurally as&#xD;
      necessary per investigator discretion. Subjects in this study must have an adequate acoustic&#xD;
      window in the abdominal space in order to be eligible for enrollment. All patients who&#xD;
      undergo ablation with the investigation device will be treated in a hospital environment&#xD;
      under general anesthesia not to exceed four hours.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 21, 2018</start_date>
  <completion_date type="Actual">July 17, 2019</completion_date>
  <primary_completion_date type="Actual">May 15, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute Technical Performance of the VORTX Rx® Medical Device for the Ablation of Primary and Metastatic Liver Tumors</measure>
    <time_frame>1-day post ablation</time_frame>
    <description>Number of Lesions that were Successfully Ablated according to technical success definition established in the protocol.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety Profile of the VORTX Rx. Incidence of Adverse Events (Serious and Non-serious) That Are Probably or Definitely Device-related</measure>
    <time_frame>2 months</time_frame>
    <description>Number of Adverse Events (Serious and Non-serious) That Are Probably or Definitely Device-related</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local Tumor Progression</measure>
    <time_frame>1 week, 1 month and 2 months post-procedure.</time_frame>
    <description>Number of patients who have indicated local tumor progression in at least one visit (1 week, 1 month, 2 months) for each tumor ablated.&#xD;
The ablation zone will be assessed post-procedurally to evaluate local tumor progression by contrast-enhanced MRI imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Involution of the Ablation Zone</measure>
    <time_frame>24hours, 1 week, 1 month and 2 months, post-procedure.</time_frame>
    <description>The involution of the ablation zone will be assessed post-procedurally by contrast-enhanced MRI imaging at 24h, 1 week, 1 month and 2 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Liver panel_Part 1</measure>
    <time_frame>Screening, 24 hours, 1 week, 1 month and 2 months.</time_frame>
    <description>Liver panel will be evaluated on the basis of the change of aspartate transaminase (AST), alanine transaminase (ALT), alkaline phosphatase, gamma glutamyl transpeptidase (GGT) from baseline to evaluation visits 24 hours, 1 week and 1 and 2 months post procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Liver Panel_Part 2</measure>
    <time_frame>24 hours, 1 week and 1 month and 2 months</time_frame>
    <description>Liver panel will be evaluated on the basis of the change of albumin from baseline to evaluation visits 24 hours, 1 week and 1 and 2 months post procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Liver Panel_Part 3</measure>
    <time_frame>24 hours, 1 week and 1month and 2 months</time_frame>
    <description>Liver panel will be evaluated on the basis of the change of bilirubin from baseline to evaluation visits 24 hours, 1 week and 1 and 2 months post procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Liver Panel_part 4</measure>
    <time_frame>24 hours, 1 week and 1month and 2 months</time_frame>
    <description>Liver panel will be evaluated on the basis of the change of prothrombin time (PT) from baseline to evaluation visits 24 hours, 1 week and 1 and 2 months post procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Liver Panel_Part 5</measure>
    <time_frame>24 hours, 1 week and 1 month and 2 months</time_frame>
    <description>Liver panel will be evaluated on the basis of the change of International normalized ratio (INR = A system established by the World Health Organization (WHO) and the International Committee on Thrombosis and Hemostasis for reporting the results of blood coagulation (clotting) tests) from baseline to evaluation visits 24 hours, 1 week and 1 and 2 months post procedure.&#xD;
The INR is derived from prothrombin time (PT) which is calculated as a ratio of the patient's PT to a control PT standardized for the potency of the thromboplastin reagent developed by the World Health Organization (WHO) using the following formula: INR = Patient PT ÷ Control PT.&#xD;
Normal values for INR: 0.9-1.3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunologic Assessment_Part 1</measure>
    <time_frame>Baseline/Screening, 1-day post ablation, 1 week and 1 and 2 months post procedure</time_frame>
    <description>Immunological response of ablation will be evaluated on the basis of immune tests conducted and tumor biomarker assessments (including, but not limited to, immune tests: CD3+, CD4+, CD8+, CD45+, CD16+, CD56+ and CD19+ from Baseline/Screening to 1-day post ablation, 1 week and 1 and 2 months post procedureprocedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunologic Assessment_Part 2</measure>
    <time_frame>Screening, 24 hours, 1 week and 1 and 2 months post procedure.</time_frame>
    <description>Immunological response of ablation will be evaluated on the basis of immune tests conducted and tumor biomarker assessments: C-reactive protein [CRP], from baseline to evaluation visits 1 day, 1 week and 1 and 2 months post procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunologic Assessment_Part 3</measure>
    <time_frame>Screening, 24 hours post ablation, 1 week and 1 and 2 months post procedure.</time_frame>
    <description>Immunological response of ablation will be evaluated on the basis of immune tests conducted and tumor biomarker assessments (including, but not limited to, immune tests): complement C3 and C4, immunoglobulins [IgG, IgM, IgA] from baseline to evaluation visits 1 day, 1 week and 1 and 2 months post procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunologic Assessment_Part 4</measure>
    <time_frame>Screening, 24 hours post ablation, 1 week and 1 and 2 months post procedure.</time_frame>
    <description>Immunological response of ablation will be evaluated on the basis of immune tests conducted and tumor biomarker assessments (including, but not limited to, immune tests: complement CH50, alfa-fetoprotein [AFP], Cancer Antigens CA15-3 [Breast Cancer] and CA 19-9 [Pancreatic Cancer]) from baseline to evaluation visits 1 day, 1 week and 1 and 2 months post procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunologic Assessment_Part 5</measure>
    <time_frame>Screening, 24 hours post ablation, 1 week and 1 and 2 months post procedure.</time_frame>
    <description>Immunological response of ablation will be evaluated on the basis of immune tests conducted and tumor biomarker assessments (including, but not limited to, immune tests): interleukin-6 [IL-6] from baseline to evaluation visits 1 day, 1 week and 1 and 2 months post procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunologic Assessment_Part 6</measure>
    <time_frame>Screening, 24 hours post ablation, 1 week and 1 and 2 months post procedure.</time_frame>
    <description>Immunological response of ablation will be evaluated on the basis of immune tests conducted and tumor biomarker assessments (including, but not limited to, immune tests): carcinoembryonic antigen [CEA] from baseline to evaluation visits 1 day, 1 week and 1 and 2 months post procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assesment of Quality of Life by Using Patient Questtionaires EORTC QLQ-C30. (European Organization for Research and Treatment of Cancer)</measure>
    <time_frame>Screening, 1 and 2 months post procedure.</time_frame>
    <description>The EORTC QLQ-C30 is a 30-item generic health-related QoL instrument designed to assess cancer patients' physical, psychological and social functioning. It is composed of 9 multi-item scales (5 functional scales [physical, role, cognitive, emotional, and social], a global QoL scale [GQoL], and 3 symptom scales [fatigue, pain, and nausea and vomiting]), 5 single-item symptom scales assessing additional symptoms commonly reported by cancer patients (dyspnoea, loss of appetite, insomnia, constipation and diarrhea), and an item on the perceived financial impact of the disease.&#xD;
All of the scales and single-item measures range in score from 0-100. A high scale score represents a higher response level. Thus, a high score for a functional scale represents a high/healthy level of functioning. A high score for the global health status/QoL represents a high QoL. However, a high score for a symptom scale/item represents a high level of symptomatology/problems.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Assessment by VAS Scale</measure>
    <time_frame>1-day post ablation and 1 week post procedure.</time_frame>
    <description>Perform pain assessment by a 100 mm visual analog scale (VAS) where 0 is &quot;no pain&quot; and 100 is &quot;the maximum pain possible&quot; at 1-day and 1-week post-procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analgesic Requirements After the Ablation Procedure</measure>
    <time_frame>in the 24-hour period post-procedure and during the one week period post-procedure</time_frame>
    <description>Evaluate analgesic treatment prescription in the 24-hour period post-procedure and during the one week period post-procedure.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Carcinoma, Hepatocellular</condition>
  <condition>Liver Metastases</condition>
  <arm_group>
    <arm_group_label>VORTX Rx treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Focused ultrasound ablation of liver tumors.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>VORTX Rx treatment</intervention_name>
    <description>Cavitation-based cellular destruction using focused ultrasound</description>
    <arm_group_label>VORTX Rx treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent before any study procedure is performed.&#xD;
&#xD;
          -  Subjects of both sexes aged 18 years or older.&#xD;
&#xD;
          -  Patients diagnosed with liver cancer, including HCC or liver metastases from breast,&#xD;
             pancreas and/or colorectal cancers. If biopsy is required, there will be a minimum of&#xD;
             2-week period after biopsy and before the ablation.&#xD;
&#xD;
          -  HCC patients must meet the United Network for Organ Sharing and Organ Procurement and&#xD;
             Transplantation Network (UNOS-OPTN) class 5 criteria for HCC (52).&#xD;
&#xD;
          -  Liver metastases patients must meet minimum criteria of liver biopsy and/or tissue&#xD;
             diagnosis of primary tumor or metastatic tumor with new or growing liver tumors&#xD;
             radiologically consistent with metastases.&#xD;
&#xD;
          -  Patients with liver cancer not candidates for surgical resection and/or not suitable&#xD;
             for other locoregional treatments or patients who have not responded to or relapsed&#xD;
             from conventional therapies.&#xD;
&#xD;
          -  Previous treatment with chemotherapy and/or radiotherapy is permitted provided that&#xD;
             these treatments have been discontinued more than 2 weeks before the ablation and&#xD;
             whenever patients have recovered from any related toxicity (53).&#xD;
&#xD;
          -  Previous treatment with immunotherapies is permitted provided that these therapies&#xD;
             have been discontinued at least 4 weeks before the ablation and whenever patients have&#xD;
             recovered from any related toxicity.&#xD;
&#xD;
          -  Previous ablation/surgery on other tumors different from those that will be targeted&#xD;
             with the VORTX Rx® is allowed whenever a minimum of 2 weeks has elapsed since the&#xD;
             prior procedure(s).&#xD;
&#xD;
          -  Tumor to be targeted for ablation will be clearly separated from other tumors or other&#xD;
             critical areas (i.e. located in different segments of the liver) and located in&#xD;
             segment 2, 3, 4, 5 or 6.&#xD;
&#xD;
          -  Largest diameter of targeted tumor ≤3 cm.&#xD;
&#xD;
          -  Tumor that will be targeted at a depth &lt;10 cm from the skin surface.&#xD;
&#xD;
          -  Must have an adequate acoustic window in the abdominal space to be able to visualize&#xD;
             targeted tumor using ultrasound imaging; also must be able to visualize targeted tumor&#xD;
             using MRI with optional CT imaging at investigator discretion.&#xD;
&#xD;
          -  Patients who can undergo general anesthesia.&#xD;
&#xD;
          -  Liver function score of Child-Pugh A or Child-Pugh B.&#xD;
&#xD;
          -  ECOG PS 0, 1 or 2 at screening.&#xD;
&#xD;
          -  Adequate liver function (ALT and AST &lt; 2.5 x upper limit of normal [ULN]), renal&#xD;
             function (serum creatinine &lt;2 ULN and/or bilirubin &lt;2.5 UNL) and hematologic function&#xD;
             (neutrophil count &gt; 1.0 x 109/L and platelet &gt; 50 x 109/L).&#xD;
&#xD;
          -  An INR &lt;2 within the last 7 days prior to the ablation in patients receiving&#xD;
             anticoagulants, and an INR &lt;1.5 for patients not treated with anticoagulants.&#xD;
&#xD;
          -  Platelets level &gt;50 x 109/L within the last 7 days prior to the ablation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who decline or are unable to understand, provide or are unwilling to sign an&#xD;
             informed consent form.&#xD;
&#xD;
          -  Pregnant or nursing (lactating) women; women of childbearing potential and sexually&#xD;
             active that are unwilling to use adequate contraception (such as oral contraceptives,&#xD;
             intrauterine contraceptive device or barrier method with spermicide or surgical&#xD;
             sterilization).&#xD;
&#xD;
          -  Targeted tumor not clearly separated (i.e. located in the same liver segment as&#xD;
             another tumor).&#xD;
&#xD;
          -  Targeted tumor located in liver segments 1, 7 or 8.&#xD;
&#xD;
          -  Targeted tumor &gt;3 cm.&#xD;
&#xD;
          -  Tumor that will be targeted &gt;10 cm from the skin surface.&#xD;
&#xD;
          -  Tumor not clearly visible with diagnostic ultrasound and MRI.&#xD;
&#xD;
          -  Liver function score of Child-Pugh C.&#xD;
&#xD;
          -  Liver volume reserve &lt;40% as measured by CT Scan (54).&#xD;
&#xD;
          -  Major surgical procedure, biopsy or significant traumatic injury &lt;2 weeks prior to the&#xD;
             procedure or has not recovered from side effects/complications of such procedure or&#xD;
             trauma.&#xD;
&#xD;
          -  Patient who has not recovered to grade 1 or better from any AEs (except alopecia,&#xD;
             fatigue, nausea, vomiting) related to previous anti neoplastic therapies.&#xD;
&#xD;
          -  BMI &gt;30.&#xD;
&#xD;
          -  Parkinson's disease.&#xD;
&#xD;
          -  History of bleeding disorders (e.g. von Willebrand disease) or patients suspected to&#xD;
             have a bleeding disorder.&#xD;
&#xD;
          -  Not able to temporarily discontinue warfarin, clopidogrel or any other long-acting&#xD;
             anticoagulants at least two weeks before the procedure.&#xD;
&#xD;
          -  Initiation of any anticancer treatment during the screening period and during the&#xD;
             follow-up study visits.&#xD;
&#xD;
          -  Life expectancy to be less than 6 months.&#xD;
&#xD;
          -  Unable or unwilling to complete all required screening and/or follow-up assessments.&#xD;
&#xD;
          -  Patients under ongoing treatment with an investigational medication or medical device&#xD;
             that conflicts with the study device.&#xD;
&#xD;
          -  Patients for whom the investigator considers that the ablation is not in the patient's&#xD;
             best interest.&#xD;
&#xD;
          -  Patients with active alcohol or drug addiction or any other condition that, in the&#xD;
             investigator's opinion, would interfere with their ability to comply with the study&#xD;
             requirements.&#xD;
&#xD;
          -  Patients with any concurrent condition that, in the investigator's opinion, would&#xD;
             jeopardize the safety of the patient or compliance with the protocol.&#xD;
&#xD;
          -  Patients with known sensitivity to iodine.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joan Vidal Jove, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mutua Terrassa , Barcelona, Spain</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinica Diagonal</name>
      <address>
        <city>Esplugues De Llobregat</city>
        <state>Barcelona</state>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital universitario Mutua Terrassa</name>
      <address>
        <city>Terrassa</city>
        <state>Barcelona</state>
        <zip>08221</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d´Hebrón</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>July 19, 2018</study_first_submitted>
  <study_first_submitted_qc>November 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2018</study_first_posted>
  <results_first_submitted>December 15, 2020</results_first_submitted>
  <results_first_submitted_qc>February 8, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 25, 2021</results_first_posted>
  <last_update_submitted>March 25, 2021</last_update_submitted>
  <last_update_submitted_qc>March 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 26, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/88/NCT03741088/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 1, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/88/NCT03741088/SAP_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 26, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/88/NCT03741088/ICF_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>VORTX Rx Treatment</title>
          <description>Focused ultrasound ablation of liver tumors.&#xD;
VORTX Rx treatment: Cavitation-based cellular destruction using focused ultrasound</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>VORTX Rx Treatment</title>
          <description>Focused ultrasound ablation of liver tumors.&#xD;
VORTX Rx treatment: Cavitation-based cellular destruction using focused ultrasound</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.1" spread="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Type of live tumors</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hepatocellular carcinoma</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Liver metastasis</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.1" lower_limit="18.9" upper_limit="28.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Eastern Cooperative Oncology Group (ECOG) Performance Status</title>
          <description>0 - Fully active, able to carry on all pre-disease performance without restriction&#xD;
- Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work&#xD;
- Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours&#xD;
Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours&#xD;
- Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair&#xD;
Dead</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>ECOG 0</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>ECOG 1</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Acute Technical Performance of the VORTX Rx® Medical Device for the Ablation of Primary and Metastatic Liver Tumors</title>
        <description>Number of Lesions that were Successfully Ablated according to technical success definition established in the protocol.</description>
        <time_frame>1-day post ablation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VORTX Rx Treatment</title>
            <description>Focused ultrasound ablation of liver tumors.&#xD;
VORTX Rx treatment: Cavitation-based cellular destruction using focused ultrasound</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Technical Performance of the VORTX Rx® Medical Device for the Ablation of Primary and Metastatic Liver Tumors</title>
          <description>Number of Lesions that were Successfully Ablated according to technical success definition established in the protocol.</description>
          <units>lesions</units>
          <param>Count of Units</param>
          <units_analyzed>lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Profile of the VORTX Rx. Incidence of Adverse Events (Serious and Non-serious) That Are Probably or Definitely Device-related</title>
        <description>Number of Adverse Events (Serious and Non-serious) That Are Probably or Definitely Device-related</description>
        <time_frame>2 months</time_frame>
        <population>Although only 5 participants performed all protocol visits, adverse events from all patients were reported and analyzed.&#xD;
Any of the 55 AEs reported was device-related.</population>
        <group_list>
          <group group_id="O1">
            <title>VORTX Rx Treatment</title>
            <description>Focused ultrasound ablation of liver tumors.&#xD;
VORTX Rx treatment: Cavitation-based cellular destruction using focused ultrasound</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Profile of the VORTX Rx. Incidence of Adverse Events (Serious and Non-serious) That Are Probably or Definitely Device-related</title>
          <description>Number of Adverse Events (Serious and Non-serious) That Are Probably or Definitely Device-related</description>
          <population>Although only 5 participants performed all protocol visits, adverse events from all patients were reported and analyzed.&#xD;
Any of the 55 AEs reported was device-related.</population>
          <units>Adverse Events</units>
          <param>Number</param>
          <units_analyzed>Adverse Events</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Adverse Events</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Local Tumor Progression</title>
        <description>Number of patients who have indicated local tumor progression in at least one visit (1 week, 1 month, 2 months) for each tumor ablated.&#xD;
The ablation zone will be assessed post-procedurally to evaluate local tumor progression by contrast-enhanced MRI imaging</description>
        <time_frame>1 week, 1 month and 2 months post-procedure.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VORTX Rx Treatment</title>
            <description>Focused ultrasound ablation of liver tumors.&#xD;
VORTX Rx treatment: Cavitation-based cellular destruction using focused ultrasound</description>
          </group>
        </group_list>
        <measure>
          <title>Local Tumor Progression</title>
          <description>Number of patients who have indicated local tumor progression in at least one visit (1 week, 1 month, 2 months) for each tumor ablated.&#xD;
The ablation zone will be assessed post-procedurally to evaluate local tumor progression by contrast-enhanced MRI imaging</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Progression: YES</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Progression: NO</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Progression: No data</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Involution of the Ablation Zone</title>
        <description>The involution of the ablation zone will be assessed post-procedurally by contrast-enhanced MRI imaging at 24h, 1 week, 1 month and 2 months</description>
        <time_frame>24hours, 1 week, 1 month and 2 months, post-procedure.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VORTX Rx Treatment</title>
            <description>Focused ultrasound ablation of liver tumors.&#xD;
VORTX Rx treatment: Cavitation-based cellular destruction using focused ultrasound</description>
          </group>
        </group_list>
        <measure>
          <title>Involution of the Ablation Zone</title>
          <description>The involution of the ablation zone will be assessed post-procedurally by contrast-enhanced MRI imaging at 24h, 1 week, 1 month and 2 months</description>
          <units>cubic centimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ablation zone volume (cm3): 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5500" spread="6.34405"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ablation zone volume (cm3): 1 week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5000" spread="9.56682"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ablation zone volume (cm3): 1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9383" spread="10.02174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ablation zone volume (cm3): 2 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7683" spread="9.47795"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Liver panel_Part 1</title>
        <description>Liver panel will be evaluated on the basis of the change of aspartate transaminase (AST), alanine transaminase (ALT), alkaline phosphatase, gamma glutamyl transpeptidase (GGT) from baseline to evaluation visits 24 hours, 1 week and 1 and 2 months post procedure.</description>
        <time_frame>Screening, 24 hours, 1 week, 1 month and 2 months.</time_frame>
        <population>Only 4 patients have these parameters determined in all study points (screening, 24h, 1 day, 1 month and 2 months post-ablation)</population>
        <group_list>
          <group group_id="O1">
            <title>VORTX Rx Treatment</title>
            <description>Focused ultrasound ablation of liver tumors.&#xD;
VORTX Rx treatment: Cavitation-based cellular destruction using focused ultrasound</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Liver panel_Part 1</title>
          <description>Liver panel will be evaluated on the basis of the change of aspartate transaminase (AST), alanine transaminase (ALT), alkaline phosphatase, gamma glutamyl transpeptidase (GGT) from baseline to evaluation visits 24 hours, 1 week and 1 and 2 months post procedure.</description>
          <population>Only 4 patients have these parameters determined in all study points (screening, 24h, 1 day, 1 month and 2 months post-ablation)</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>ablation procedures</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>ablation procedures</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AST Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.7500" spread="33.83662"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="183.5000" spread="80.71555"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST 1 week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.0000" spread="25.17936"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST 1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.7500" spread="10.68878"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST 2 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.5000" spread="19.94158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.0000" spread="22.13594"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139.0000" spread="56.12486"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT 1 week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.5000" spread="30.27100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT 1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.5000" spread="12.60952"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT 2 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.0000" spread="15.55635"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127.2500" spread="105.05673"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118.0000" spread="111.48692"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT 1 week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="159.7500" spread="176.57364"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT 1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="162.5000" spread="139.50986"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT 2 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102.5000" spread="43.23964"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline Phosphatase Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="156.5000" spread="139.89639"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline Phosphatase 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127.2500" spread="67.14847"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline Phosphatase 1 week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="165.0000" spread="88.67168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline Phosphatase 1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146.7500" spread="66.33941"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline Phosphatase 2 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130.2500" spread="74.44629"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Liver Panel_Part 2</title>
        <description>Liver panel will be evaluated on the basis of the change of albumin from baseline to evaluation visits 24 hours, 1 week and 1 and 2 months post procedure.</description>
        <time_frame>24 hours, 1 week and 1 month and 2 months</time_frame>
        <population>Only 4 patients have these parameters determined in all study points (screening, 24h, 1 day, 1 month and 2 months post-ablation)</population>
        <group_list>
          <group group_id="O1">
            <title>VORTX Rx Treatment</title>
            <description>Focused ultrasound ablation of liver tumors.&#xD;
VORTX Rx treatment: Cavitation-based cellular destruction using focused ultrasound</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Liver Panel_Part 2</title>
          <description>Liver panel will be evaluated on the basis of the change of albumin from baseline to evaluation visits 24 hours, 1 week and 1 and 2 months post procedure.</description>
          <population>Only 4 patients have these parameters determined in all study points (screening, 24h, 1 day, 1 month and 2 months post-ablation)</population>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>ablation procedures</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>ablation procedures</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Albumin Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.0250" spread="2.88603"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.7500" spread="1.13284"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin 1 week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.5250" spread="1.95683"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin 1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.3750" spread="0.63966"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin 2 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.1750" spread="1.65806"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Liver Panel_Part 3</title>
        <description>Liver panel will be evaluated on the basis of the change of bilirubin from baseline to evaluation visits 24 hours, 1 week and 1 and 2 months post procedure</description>
        <time_frame>24 hours, 1 week and 1month and 2 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VORTX Rx Treatment</title>
            <description>Focused ultrasound ablation of liver tumors.&#xD;
VORTX Rx treatment: Cavitation-based cellular destruction using focused ultrasound</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Liver Panel_Part 3</title>
          <description>Liver panel will be evaluated on the basis of the change of bilirubin from baseline to evaluation visits 24 hours, 1 week and 1 and 2 months post procedure</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>ablation procedures</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>ablation procedures</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Bilirrubin Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7525" spread="0.42578"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirrubin 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6425" spread="0.20549"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirrubin 1 week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7600" spread="0.32934"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirrubin 1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5250" spread="0.11561"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirrubin 2 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7050" spread="0.31268"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Liver Panel_part 4</title>
        <description>Liver panel will be evaluated on the basis of the change of prothrombin time (PT) from baseline to evaluation visits 24 hours, 1 week and 1 and 2 months post procedure</description>
        <time_frame>24 hours, 1 week and 1month and 2 months</time_frame>
        <population>Only 4 patients have these parameters determined in all study points (screening, 24h, 1 day, 1 month and 2 months post-ablation)</population>
        <group_list>
          <group group_id="O1">
            <title>VORTX Rx Treatment</title>
            <description>Focused ultrasound ablation of liver tumors.&#xD;
VORTX Rx treatment: Cavitation-based cellular destruction using focused ultrasound</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Liver Panel_part 4</title>
          <description>Liver panel will be evaluated on the basis of the change of prothrombin time (PT) from baseline to evaluation visits 24 hours, 1 week and 1 and 2 months post procedure</description>
          <population>Only 4 patients have these parameters determined in all study points (screening, 24h, 1 day, 1 month and 2 months post-ablation)</population>
          <units>percentage of activity</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>ablation procedures</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>ablation procedures</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Prothrombin time Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.2500" spread="5.50000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prothrombin time 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.5000" spread="9.94987"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prothrombin time 1 week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.7500" spread="8.38153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prothrombin time 1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.7500" spread="2.50000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prothrombin time 2 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.2500" spread="17.50000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Liver Panel_Part 5</title>
        <description>Liver panel will be evaluated on the basis of the change of International normalized ratio (INR = A system established by the World Health Organization (WHO) and the International Committee on Thrombosis and Hemostasis for reporting the results of blood coagulation (clotting) tests) from baseline to evaluation visits 24 hours, 1 week and 1 and 2 months post procedure.&#xD;
The INR is derived from prothrombin time (PT) which is calculated as a ratio of the patient's PT to a control PT standardized for the potency of the thromboplastin reagent developed by the World Health Organization (WHO) using the following formula: INR = Patient PT ÷ Control PT.&#xD;
Normal values for INR: 0.9-1.3.</description>
        <time_frame>24 hours, 1 week and 1 month and 2 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VORTX Rx Treatment</title>
            <description>Focused ultrasound ablation of liver tumors.&#xD;
VORTX Rx treatment: Cavitation-based cellular destruction using focused ultrasound</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Liver Panel_Part 5</title>
          <description>Liver panel will be evaluated on the basis of the change of International normalized ratio (INR = A system established by the World Health Organization (WHO) and the International Committee on Thrombosis and Hemostasis for reporting the results of blood coagulation (clotting) tests) from baseline to evaluation visits 24 hours, 1 week and 1 and 2 months post procedure.&#xD;
The INR is derived from prothrombin time (PT) which is calculated as a ratio of the patient's PT to a control PT standardized for the potency of the thromboplastin reagent developed by the World Health Organization (WHO) using the following formula: INR = Patient PT ÷ Control PT.&#xD;
Normal values for INR: 0.9-1.3.</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>ablation procedures</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>ablation procedures</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>INR Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0500" spread="0.5774"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>INR 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0750" spread="0.09574"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>INR 1 week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0500" spread="0.05774"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>INR 1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0250" spread="0.05000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>INR 2 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0750" spread="0.15000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunologic Assessment_Part 1</title>
        <description>Immunological response of ablation will be evaluated on the basis of immune tests conducted and tumor biomarker assessments (including, but not limited to, immune tests: CD3+, CD4+, CD8+, CD45+, CD16+, CD56+ and CD19+ from Baseline/Screening to 1-day post ablation, 1 week and 1 and 2 months post procedureprocedure.</description>
        <time_frame>Baseline/Screening, 1-day post ablation, 1 week and 1 and 2 months post procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VORTX Rx Treatment</title>
            <description>Focused ultrasound ablation of liver tumors.&#xD;
VORTX Rx treatment: Cavitation-based cellular destruction using focused ultrasound</description>
          </group>
        </group_list>
        <measure>
          <title>Immunologic Assessment_Part 1</title>
          <description>Immunological response of ablation will be evaluated on the basis of immune tests conducted and tumor biomarker assessments (including, but not limited to, immune tests: CD3+, CD4+, CD8+, CD45+, CD16+, CD56+ and CD19+ from Baseline/Screening to 1-day post ablation, 1 week and 1 and 2 months post procedureprocedure.</description>
          <units>cells/uL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>ablation procedures</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>ablation procedures</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD3+ (T cells) Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="801.7500" spread="374.33708"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD3+ (T cells) 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="618.2500" spread="365.48814"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD3+ (T cells) 1 week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="713.7500" spread="234.09596"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD3+ (T cells) 1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="587.7500" spread="253.11575"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD3+ (T cells) 2 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="632.0000" spread="150.53017"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+ (T helper cells) Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="469.2500" spread="146.20619"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+ (T helper cells) 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="374.7500" spread="128.99709"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+ (T helper cells) 1 week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="445.2500" spread="121.94637"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+ (T helper cells) 1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="357.0000" spread="159.34240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+ (T helper cells) 2 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="382.2500" spread="77.24150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8+ (T suppressor/cytotoxic cells) Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="262.7500" spread="223.82638"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8+ (T suppressor/cytotoxic cells) 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="220.5000" spread="204.31593"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8+ (T suppressor/cytotoxic cells) 1 week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="230.5000" spread="139.01679"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8+ (T suppressor/cytotoxic cells) 1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="186.7500" spread="136.19196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8+ (T suppressor/cytotoxic cells) 2 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="177.2500" spread="85.47660"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD45+ (leucocyte common antigen) Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1054.1425" spread="384.46746"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD45+ (leucocyte common antigen) 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="843.0350" spread="349.94733"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD45+ (leucocyte common antigen) 1 week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="938.3700" spread="251.60549"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD45+ (leucocyte common antigen) 1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="788.4275" spread="257.71702"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD45+ (leucocyte common antigen) 2 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="831.2675" spread="194.76464"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD16+ Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134.3000" spread="69.78811"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD16+ 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.4750" spread="50.40353"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD16+ 1 week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116.1750" spread="65.72460"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD16+ 1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109.7500" spread="53.11230"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD16+ 2 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.5000" spread="47.59202"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD56+ (NKT cells) Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.4500" spread="85.14507"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD56+ (NKT cells) 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.5000" spread="61.00213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD56+ (NKT cells) 1 week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.9500" spread="69.58934"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD56+ (NKT cells) 1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.2500" spread="68.07533"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD56+ (NKT cells) 2 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.7500" spread="50.12900"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD19+ (B-lymphocyte antigen) Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.0000" spread="58.66856"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD19+ (B-lymphocyte antigen) 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.5000" spread="58.31238"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD19+ (B-lymphocyte antigen) 1 week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.5000" spread="53.10053"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD19+ (B-lymphocyte antigen) 1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.0000" spread="50.51732"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD19+ (B-lymphocyte antigen) 2 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.0000" spread="51.71718"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunologic Assessment_Part 2</title>
        <description>Immunological response of ablation will be evaluated on the basis of immune tests conducted and tumor biomarker assessments: C-reactive protein [CRP], from baseline to evaluation visits 1 day, 1 week and 1 and 2 months post procedure.</description>
        <time_frame>Screening, 24 hours, 1 week and 1 and 2 months post procedure.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VORTX Rx Treatment</title>
            <description>Focused ultrasound ablation of liver tumors.&#xD;
VORTX Rx treatment: Cavitation-based cellular destruction using focused ultrasound</description>
          </group>
        </group_list>
        <measure>
          <title>Immunologic Assessment_Part 2</title>
          <description>Immunological response of ablation will be evaluated on the basis of immune tests conducted and tumor biomarker assessments: C-reactive protein [CRP], from baseline to evaluation visits 1 day, 1 week and 1 and 2 months post procedure.</description>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>ablation procedures</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>ablation procedures</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>C reactive protein Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9750" spread="5.67355"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C reactive protein 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0250" spread="7.06323"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C reactive protein 1 week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.8250" spread="53.05735"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C reactive protein 1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7750" spread="3.57713"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C reactive protein 2 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.9500" spread="8.85795"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunologic Assessment_Part 3</title>
        <description>Immunological response of ablation will be evaluated on the basis of immune tests conducted and tumor biomarker assessments (including, but not limited to, immune tests): complement C3 and C4, immunoglobulins [IgG, IgM, IgA] from baseline to evaluation visits 1 day, 1 week and 1 and 2 months post procedure.</description>
        <time_frame>Screening, 24 hours post ablation, 1 week and 1 and 2 months post procedure.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VORTX Rx Treatment</title>
            <description>Focused ultrasound ablation of liver tumors.&#xD;
VORTX Rx treatment: Cavitation-based cellular destruction using focused ultrasound</description>
          </group>
        </group_list>
        <measure>
          <title>Immunologic Assessment_Part 3</title>
          <description>Immunological response of ablation will be evaluated on the basis of immune tests conducted and tumor biomarker assessments (including, but not limited to, immune tests): complement C3 and C4, immunoglobulins [IgG, IgM, IgA] from baseline to evaluation visits 1 day, 1 week and 1 and 2 months post procedure.</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>ablation procedures</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>ablation procedures</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complement C3 Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144.0000" spread="53.61592"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complement C3 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123.2000" spread="25.76354"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complement C3 1 week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="150.5000" spread="22.75229"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complement C3 1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143.9000" spread="44.60239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complement C3 2 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134.7500" spread="26.88711"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complement C4 Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.7750" spread="20.29949"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complement C4 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.7750" spread="6.58401"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complement C4 1 week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.8250" spread="9.00717"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complement C4 1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.9500" spread="11.01348"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complement C4 2 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.0750" spread="14.47236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgG Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="867.2500" spread="326.38359"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgG 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="792.9000" spread="354.83048"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgG 1 week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="856.0000" spread="335.22430"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgG 1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="916.7500" spread="338.63784"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgG 2 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="899.0000" spread="334.19655"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgM Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132.6250" spread="59.75139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgM 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120.9000" spread="51.44745"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgM 1 week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132.3500" spread="45.62846"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgM 1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140.7500" spread="43.69115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgM 2 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141.2500" spread="52.94075"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgA Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147.5000" spread="133.49871"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgA 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130.0000" spread="119.05766"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgA 1 week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142.8000" spread="131.15955"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgA 1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145.9500" spread="116.11530"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgA 2 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="129.3750" spread="84.51147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunologic Assessment_Part 4</title>
        <description>Immunological response of ablation will be evaluated on the basis of immune tests conducted and tumor biomarker assessments (including, but not limited to, immune tests: complement CH50, alfa-fetoprotein [AFP], Cancer Antigens CA15-3 [Breast Cancer] and CA 19-9 [Pancreatic Cancer]) from baseline to evaluation visits 1 day, 1 week and 1 and 2 months post procedure.</description>
        <time_frame>Screening, 24 hours post ablation, 1 week and 1 and 2 months post procedure.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VORTX Rx Treatment</title>
            <description>Focused ultrasound ablation of liver tumors.&#xD;
VORTX Rx treatment: Cavitation-based cellular destruction using focused ultrasound</description>
          </group>
        </group_list>
        <measure>
          <title>Immunologic Assessment_Part 4</title>
          <description>Immunological response of ablation will be evaluated on the basis of immune tests conducted and tumor biomarker assessments (including, but not limited to, immune tests: complement CH50, alfa-fetoprotein [AFP], Cancer Antigens CA15-3 [Breast Cancer] and CA 19-9 [Pancreatic Cancer]) from baseline to evaluation visits 1 day, 1 week and 1 and 2 months post procedure.</description>
          <units>U/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>ablation procedures</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>ablation procedures</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complement CH50 Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.7500" spread="26.87471"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complement CH50 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.5000" spread="37.59876"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complement CH50 1 week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.0000" spread="34.02940"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complement CH50 1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.2500" spread="24.18505"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complement CH50 2 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.2500" spread="36.59121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AFP Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="544.8050" spread="1084.79682"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AFP 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="417.8550" spread="831.43014"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AFP 1 week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="502.2350" spread="999.84372"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AFP 1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="264.1675" spread="523.22173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AFP 2 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="224.5900" spread="441.61247"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CA 15-3 (breast cancer) Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.8500" spread="9.02940"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CA 15-3 (breast cancer) 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.0000" spread="6.66433"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CA 15-3 (breast cancer) 1 week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3750" spread="7.20804"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CA 15-3 (breast cancer) 1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.2250" spread="9.31786"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CA 15-3 (breast cancer) 2months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.4250" spread="7.08396"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CA 19-9 (pancreatic cancer) Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="167.8175" spread="300.24702"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CA 19-9 (pancreatic cancer) 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="174.8450" spread="312.86710"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CA 19-9 (pancreatic cancer) 1 week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="169.1675" spread="290.56204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CA 19-9 (pancreatic cancer) 1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="168.1200" spread="285.77017"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CA 19-9 (pancreatic cancer) 2 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="256.9525" spread="475.14915"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunologic Assessment_Part 5</title>
        <description>Immunological response of ablation will be evaluated on the basis of immune tests conducted and tumor biomarker assessments (including, but not limited to, immune tests): interleukin-6 [IL-6] from baseline to evaluation visits 1 day, 1 week and 1 and 2 months post procedure.</description>
        <time_frame>Screening, 24 hours post ablation, 1 week and 1 and 2 months post procedure.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VORTX Rx Treatment</title>
            <description>Focused ultrasound ablation of liver tumors.&#xD;
VORTX Rx treatment: Cavitation-based cellular destruction using focused ultrasound</description>
          </group>
        </group_list>
        <measure>
          <title>Immunologic Assessment_Part 5</title>
          <description>Immunological response of ablation will be evaluated on the basis of immune tests conducted and tumor biomarker assessments (including, but not limited to, immune tests): interleukin-6 [IL-6] from baseline to evaluation visits 1 day, 1 week and 1 and 2 months post procedure.</description>
          <units>pg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>ablation procedures</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>ablation procedures</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Interleukin-6 Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2225" spread="2.88648"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin-6 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4575" spread="1.97481"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin-6 1 week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.7850" spread="14.05719"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin-6 1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8750" spread="2.37905"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin-6 2 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8125" spread="2.84372"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunologic Assessment_Part 6</title>
        <description>Immunological response of ablation will be evaluated on the basis of immune tests conducted and tumor biomarker assessments (including, but not limited to, immune tests): carcinoembryonic antigen [CEA] from baseline to evaluation visits 1 day, 1 week and 1 and 2 months post procedure.</description>
        <time_frame>Screening, 24 hours post ablation, 1 week and 1 and 2 months post procedure.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VORTX Rx Treatment</title>
            <description>Focused ultrasound ablation of liver tumors.&#xD;
VORTX Rx treatment: Cavitation-based cellular destruction using focused ultrasound</description>
          </group>
        </group_list>
        <measure>
          <title>Immunologic Assessment_Part 6</title>
          <description>Immunological response of ablation will be evaluated on the basis of immune tests conducted and tumor biomarker assessments (including, but not limited to, immune tests): carcinoembryonic antigen [CEA] from baseline to evaluation visits 1 day, 1 week and 1 and 2 months post procedure.</description>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>ablation procedures</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>ablation procedures</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CEA Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.9300" spread="50.75086"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CEA 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.4200" spread="55.16530"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CEA 1 week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.7925" spread="45.10227"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CEA 1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.6150" spread="64.11322"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CEA 2 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.0225" spread="97.45371"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assesment of Quality of Life by Using Patient Questtionaires EORTC QLQ-C30. (European Organization for Research and Treatment of Cancer)</title>
        <description>The EORTC QLQ-C30 is a 30-item generic health-related QoL instrument designed to assess cancer patients' physical, psychological and social functioning. It is composed of 9 multi-item scales (5 functional scales [physical, role, cognitive, emotional, and social], a global QoL scale [GQoL], and 3 symptom scales [fatigue, pain, and nausea and vomiting]), 5 single-item symptom scales assessing additional symptoms commonly reported by cancer patients (dyspnoea, loss of appetite, insomnia, constipation and diarrhea), and an item on the perceived financial impact of the disease.&#xD;
All of the scales and single-item measures range in score from 0-100. A high scale score represents a higher response level. Thus, a high score for a functional scale represents a high/healthy level of functioning. A high score for the global health status/QoL represents a high QoL. However, a high score for a symptom scale/item represents a high level of symptomatology/problems.</description>
        <time_frame>Screening, 1 and 2 months post procedure.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VORTX Rx Treatment</title>
            <description>Focused ultrasound ablation of liver tumors.&#xD;
VORTX Rx treatment: Cavitation-based cellular destruction using focused ultrasound</description>
          </group>
        </group_list>
        <measure>
          <title>Assesment of Quality of Life by Using Patient Questtionaires EORTC QLQ-C30. (European Organization for Research and Treatment of Cancer)</title>
          <description>The EORTC QLQ-C30 is a 30-item generic health-related QoL instrument designed to assess cancer patients' physical, psychological and social functioning. It is composed of 9 multi-item scales (5 functional scales [physical, role, cognitive, emotional, and social], a global QoL scale [GQoL], and 3 symptom scales [fatigue, pain, and nausea and vomiting]), 5 single-item symptom scales assessing additional symptoms commonly reported by cancer patients (dyspnoea, loss of appetite, insomnia, constipation and diarrhea), and an item on the perceived financial impact of the disease.&#xD;
All of the scales and single-item measures range in score from 0-100. A high scale score represents a higher response level. Thus, a high score for a functional scale represents a high/healthy level of functioning. A high score for the global health status/QoL represents a high QoL. However, a high score for a symptom scale/item represents a high level of symptomatology/problems.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>ablation procedures</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>ablation procedures</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Global health status/QoL Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.8333" spread="15.95712"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Global health status/QoL 1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.3333" spread="28.05418"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Global health status/QoL 2 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.8333" spread="25.00000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical functioning Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.6667" spread="12.61980"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical functioning 1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.3333" spread="13.87777"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical functioning 2 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.6667" spread="18.35857"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role functioning screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.5000" spread="15.95712"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role functioning 1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.8333" spread="28.46375"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role functioning 2 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.3333" spread="13.60828"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional functioning Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.5000" spread="8.33333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional functioning 1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.5000" spread="19.83730"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional functioning 2 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.3333" spread="18.00206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cognitive functioning Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.1667" spread="20.97176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cognitive functioning 1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0000" spread="21.51657"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cognitive functioning 2 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.1667" spread="31.54949"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social functioning Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.8333" spread="8.33333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social functioning 1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.3333" spread="13.60828"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social functioning 2 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.8333" spread="8.33333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.5556" spread="13.98117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue 1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.6667" spread="27.77778"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue 2 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0000" spread="24.63729"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea and vomiting Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea and vomiting 1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea and vomiting 1 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.6667" spread="23.57023"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain 1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.8333" spread="31.54949"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain 2 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.6667" spread="34.69443"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnea Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnea 1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnea 2 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insomnia Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.6667" spread="41.94352"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insomnia 1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3333" spread="47.14045"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insomnia 2 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0000" spread="31.91424"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Appetite loss Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0000" spread="50.00000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Appetite loss 1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0000" spread="43.03315"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Appetite loss 2 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3333" spread="16.66667"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Constipation Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3333" spread="16.66667"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Constipation 1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Constipation 2 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3333" spread="47.14045"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea 1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.6667" spread="19.24501"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea 2 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.6667" spread="19.24501"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Financial difficulties Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.6667" spread="19.24501"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Financial difficulties 1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3333" spread="16.66667"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Financial difficulties 2 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3333" spread="16.66667"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Assessment by VAS Scale</title>
        <description>Perform pain assessment by a 100 mm visual analog scale (VAS) where 0 is &quot;no pain&quot; and 100 is &quot;the maximum pain possible&quot; at 1-day and 1-week post-procedure.</description>
        <time_frame>1-day post ablation and 1 week post procedure.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VORTX Rx Treatment</title>
            <description>Focused ultrasound ablation of liver tumors.&#xD;
VORTX Rx treatment: Cavitation-based cellular destruction using focused ultrasound</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Assessment by VAS Scale</title>
          <description>Perform pain assessment by a 100 mm visual analog scale (VAS) where 0 is &quot;no pain&quot; and 100 is &quot;the maximum pain possible&quot; at 1-day and 1-week post-procedure.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>ablation procedures</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>ablation procedures</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>VAS score: 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAS score: 1 week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0" spread="18.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Analgesic Requirements After the Ablation Procedure</title>
        <description>Evaluate analgesic treatment prescription in the 24-hour period post-procedure and during the one week period post-procedure.</description>
        <time_frame>in the 24-hour period post-procedure and during the one week period post-procedure</time_frame>
        <population>Number of patients with at least one drug due to Post-procedure pain (concomitant medication form).</population>
        <group_list>
          <group group_id="O1">
            <title>VORTX Rx Treatment</title>
            <description>Focused ultrasound ablation of liver tumors.&#xD;
VORTX Rx treatment: Cavitation-based cellular destruction using focused ultrasound</description>
          </group>
        </group_list>
        <measure>
          <title>Analgesic Requirements After the Ablation Procedure</title>
          <description>Evaluate analgesic treatment prescription in the 24-hour period post-procedure and during the one week period post-procedure.</description>
          <population>Number of patients with at least one drug due to Post-procedure pain (concomitant medication form).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>At least one drug due to post-procedure pain: YES</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>At least one drug due to post-procedure pain: NO</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>VORTX Rx Treatment</title>
          <description>Focused ultrasound ablation of liver tumors.&#xD;
VORTX Rx treatment: Cavitation-based cellular destruction using focused ultrasound</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>FEVER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>HYPOCALCEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Gastrointestinal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>General pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Occasional fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Transaminase elevation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increase</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>ALT increase</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>AST increase</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>GGT increase</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Appetite increase</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Coccyx pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Left leg pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Malleolar edema with fovea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pain in right shoulder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pain in right side</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse reaction to analeptics and opioid receptor antagonists</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Lipotomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Sciatic pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Tingling in feet and hands</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Choluria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chest punctures</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Right basal pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Desquamative lesions</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Itchy skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Swollen ankles</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The results or conclusions of this study will be reported at scientific congresses and published in scientific journals. The investigator agrees to maintain this information in strict confidence, and will not use it for any other purpose without the written authorization of the sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Affairs Manager</name_or_title>
      <organization>HistoSonics, Inc.</organization>
      <phone>651.398.7586</phone>
      <email>christine.sullivan@histosonics.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

